ATE425463T1 - Modulation der wechselwirkung zwischen hgf-beta- kette und c-met - Google Patents

Modulation der wechselwirkung zwischen hgf-beta- kette und c-met

Info

Publication number
ATE425463T1
ATE425463T1 AT04754499T AT04754499T ATE425463T1 AT E425463 T1 ATE425463 T1 AT E425463T1 AT 04754499 T AT04754499 T AT 04754499T AT 04754499 T AT04754499 T AT 04754499T AT E425463 T1 ATE425463 T1 AT E425463T1
Authority
AT
Austria
Prior art keywords
met
modulation
interaction
beta chain
hgf
Prior art date
Application number
AT04754499T
Other languages
English (en)
Inventor
Daniel Kirchhofer
Robert LAZARUS
Xiaoyi Yao
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33555430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE425463(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE425463T1 publication Critical patent/ATE425463T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04754499T 2003-06-06 2004-06-04 Modulation der wechselwirkung zwischen hgf-beta- kette und c-met ATE425463T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47677803P 2003-06-06 2003-06-06
US53211703P 2003-12-23 2003-12-23

Publications (1)

Publication Number Publication Date
ATE425463T1 true ATE425463T1 (de) 2009-03-15

Family

ID=33555430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04754499T ATE425463T1 (de) 2003-06-06 2004-06-04 Modulation der wechselwirkung zwischen hgf-beta- kette und c-met

Country Status (17)

Country Link
US (8) US20060035278A9 (de)
EP (3) EP1636593B9 (de)
JP (1) JP2007526447A (de)
KR (2) KR20110117728A (de)
AT (1) ATE425463T1 (de)
AU (1) AU2004252475A1 (de)
CA (1) CA2528343A1 (de)
DE (1) DE602004019919D1 (de)
DK (1) DK1636593T5 (de)
ES (1) ES2323425T3 (de)
HK (1) HK1092872A1 (de)
HR (1) HRP20090324T1 (de)
MX (1) MXPA05013181A (de)
PL (1) PL1636593T3 (de)
PT (1) PT1636593E (de)
SI (1) SI1636593T1 (de)
WO (1) WO2005001486A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
TW201319088A (zh) * 2003-07-18 2013-05-16 Amgen Inc 對肝細胞生長因子具專一性之結合劑
JP2008516629A (ja) 2004-10-20 2008-05-22 ペアス インスティテュート アーベー 肝細胞増殖因子（ｈｇｆ）の生物活性に関する評価
EP2289892B1 (de) 2005-02-09 2012-08-22 ArQule, Inc. Maleimid-derivate, pharmazeutischen Zusammensetzungen, und Verfahren zur Krebsbehandlung
ZA200707953B (en) * 2005-03-25 2009-06-24 Genenthech Inc Methods and compositions for modulating hyperstabilized c-met
KR20080004514A (ko) * 2005-03-25 2008-01-09 제넨테크, 인크. 폐암에서의 ｃ-ｍｅｔ 돌연변이
EP1869070B1 (de) * 2005-04-15 2013-11-27 Genentech, Inc. Hgf-beta-kettenvarianten
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
US20110053931A1 (en) * 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
PL2101807T3 (pl) 2006-12-19 2016-11-30 Antagoniści specyficzni względem VEGF dla terapii adiuwantem i neoadiuwantem i leczenie wczesnych stadiów guzów
US8513292B2 (en) 2007-06-22 2013-08-20 Arqule, Inc. Compositions and methods for the treatment of cancer
JP5425060B2 (ja) 2007-06-22 2014-02-26 アークル インコーポレイテッド ピロリジノン、ピロリジン−２，５−ジオン、ピロリジンおよびチオスクシンイミド誘導体、癌の治療のための組成物および方法
AU2008268613A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Quinazolinone compounds and methods of use thereof
CA2743184A1 (en) * 2007-11-09 2009-05-14 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
JP2011513427A (ja) * 2008-03-06 2011-04-28 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ及びＥＧＦＲアンタゴニストの併用療法
US9157920B2 (en) * 2009-06-26 2015-10-13 Peas Institut Ab Method for determining biologically active HGF
WO2011050188A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Anti-hepsin antibodies and methods using same
KR102059663B1 (ko) 2010-03-10 2019-12-26 젠맵 에이/에스 Ｃ―ｍｅｔ에 대한 모노클로날 항체
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CN102643268B (zh) 2011-12-30 2014-05-21 沈阳药科大学 喹啉类及噌啉类化合物及其应用
WO2013143376A1 (zh) 2012-03-26 2013-10-03 武汉盛云生物医药科技有限责任公司 含1，2，4-三嗪-3，5-二酮的喹啉类化合物及其应用
RS53818B1 (en) 2012-10-12 2015-06-30 Spirogen Sàrl PIROLOBENZODIAZEPINI I NJIHOVI conjugated
BR112015023333A8 (pt) 2013-03-13 2018-04-17 Medimmune Ltd pirrolbenzodiazepinas e conjugados dos mesmos
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN107002119A (zh) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
CN113150147A (zh) 2015-03-16 2021-07-23 塞尔德克斯医疗公司 抗-met抗体及其使用方法
JP2019534882A (ja) 2016-10-11 2019-12-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 免疫介在性療法薬を有する抗体−薬物コンジュゲート
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
KR20210016562A (ko) 2018-05-23 2021-02-16 에이디씨 테라퓨틱스 에스에이 분자 애쥬번트
JP7380999B2 (ja) * 2018-09-06 2023-11-15 国立大学法人 東京大学 環状ペプチド
CN114340684A (zh) 2019-09-16 2022-04-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
CA1338518C (en) 1987-09-23 1996-08-13 Joyce M. Zarling Antibody heteroconjugates for the killing of hiv-infected cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
AU651452B2 (en) * 1991-05-10 1994-07-21 Pharmacia & Upjohn S.P.A. Truncated forms of the hepatocyte growth factor receptor
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5328837A (en) * 1992-05-18 1994-07-12 Genentech, Inc. Hepatocyte growth factor protease domain variants
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
WO1994012158A1 (en) 1992-12-02 1994-06-09 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
ES2151079T3 (es) 1994-09-09 2000-12-16 Takeda Chemical Industries Ltd Preparacion de liberacion sostenida que contiene una sal metalica de un peptido.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5647409A (en) 1995-04-04 1997-07-15 Allergan On-site syringe filling apparatus for viscoelastic materials, and corresponding method for on-site syringe filling
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
NZ310644A (en) 1995-06-07 1999-08-30 Alkermes Inc Composition for sustained release of human growth hormone
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US5911252A (en) 1997-04-29 1999-06-15 Cassel; Douglas Automated syringe filling system for radiographic contrast agents and other injectable substances
US6677377B2 (en) * 2000-06-21 2004-01-13 Georgetown University School Of Medicine Structure based discovery of inhibitors of matriptase for the treatment of cancer and other conditions

Also Published As

Publication number Publication date
KR101148657B1 (ko) 2012-07-05
WO2005001486A1 (en) 2005-01-06
ES2323425T3 (es) 2009-07-15
US20070129301A1 (en) 2007-06-07
EP2093570A1 (de) 2009-08-26
EP1636593B1 (de) 2009-03-11
US20130143813A1 (en) 2013-06-06
US20170106042A1 (en) 2017-04-20
US20110177058A1 (en) 2011-07-21
DK1636593T5 (da) 2009-07-27
EP1636593A1 (de) 2006-03-22
JP2007526447A (ja) 2007-09-13
PL1636593T3 (pl) 2009-08-31
HK1092872A1 (en) 2007-02-16
MXPA05013181A (es) 2006-06-23
EP2367008A2 (de) 2011-09-21
US20150126448A1 (en) 2015-05-07
KR20110117728A (ko) 2011-10-27
SI1636593T1 (sl) 2009-08-31
CA2528343A1 (en) 2005-01-06
KR20060017634A (ko) 2006-02-24
HRP20090324T1 (hr) 2010-02-28
DE602004019919D1 (de) 2009-04-23
US20190054138A1 (en) 2019-02-21
EP1636593B9 (de) 2009-12-16
EP2367008A3 (de) 2014-12-24
DK1636593T3 (da) 2009-06-15
PT1636593E (pt) 2009-06-03
US20060035278A9 (en) 2006-02-16
AU2004252475A1 (en) 2005-01-06
US20050037431A1 (en) 2005-02-17
US20100040634A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
ATE425463T1 (de) Modulation der wechselwirkung zwischen hgf-beta- kette und c-met
DK1644336T3 (da) Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin
NO20075412L (no) Fremgangsmater og preparater til modulering av hyperstabilisert C-MET
ATE540024T1 (de) Allosterische modulatoren von metabotropen glutamatrezeptoren
ATE512222T1 (de) Modulation der expression von diacylglycerin- acyltransferase 2
ATE492526T1 (de) Retinoid derivate mit antiangiogener, antitumor und proapoptotischer wirkung
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
BR0003184A (pt) Métodos para tratamento de pigmentação da pele
WO2003068944A3 (en) METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α-
ATE322258T1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
DE60223923D1 (de) Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
BRPI0515670A (pt) anticorpos isolados e método de tratamento de uma doença associada com descontrole da sinalização do hgf/c-met
ATE460923T1 (de) Lyophilisierung von virosomen
DK1250455T3 (da) Antisense-inhibering af PTP1B-ekspression
DK1930439T3 (da) Neurotrofe faktorer
ATE311879T1 (de) Verwendung von 3-substituierten oxidinolderivaten als kcnq kaliumkanalmodulatoren
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
ATE400273T1 (de) 1-2'-(1,4'-biperidin-1'-yl)-1-(phenyl)- ethylcyclohexanol-derivate als monoamin- wiederaufnahme-modulatoren zur behandlung von vasomotorischen symptomen
ATE469167T1 (de) Anti-infarkt-moleküle
UA93886C2 (ru) Производные четвертичного альфа-аминокарбоксамида kak модуляторы потенциалозависимых натриевых каналов
DE59907346D1 (de) Verwendung von Schwefel-organischen Verbindungen als Mittel zur bathochromen Verschiebung der UV/Vis-Absorptionsbande von Carotinoiden
ATE403665T1 (de) Verfahren und zusammensetzungen zur modulierung der gluconeogenese mit pgc-1
ATE481977T1 (de) Zusammensetzungen zur verhinderung der thrombozytenaggregation
DE60213522D1 (de) Kombination von Arnica, Ruscus und Menthol
CY1112773T1 (el) Χημικες ενωσεις της 4-οξαδιαζολυλ-πιπεριδινης και χρησεις αυτων

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1636593

Country of ref document: EP